Table 1.

Clinical and demographic characteristics of the study population.

CharacteristicWhole Sample, n = 136Minimal Disease Activity, n = 22No Minimal Disease Activity, n = 114p
Age, yrs45.62 ± 11.8237.82 ± 12.2147.12 ± 11.180.001
Male, n (%)58 (42.6)12 (54.5)46 (40.4)0.245
Clinical pattern, n (%)
  Polyarticular68 (50.0)6 (27.3)62 (54.4)0.051
  Oligoarticular22 (16.2)6 (27.3)16 (14.0)0.201
  Spondylitis46 (33.8)10 (45.5)36 (31.6)0.226
Disease duration, yrs5.19 ± 3.044.82 ± 3.405.26 ± 2.970.532
ESR, mm/h21.93 ± 16.20028.27 ± 18.7320.70 ± 15.450.044
CRP, mg/l6.02 ± 8.88611.40 ± 19.395.42 ± 6.790.043
SJC3.13 ± 4.4121.82 ± 2.033.39 ± 4.690.013
TJC13.54 ± 9.7917.45 ± 5.5814.72 ± 9.990.001
PASI0.78 ± 0.8750.82 ± 1.050.77 ± 0.840.821
HAQ1.20 ± 1.121.25 ± 1.031.68 ± 1.330.225
VAS73.4 ± 19.972.7 ± 23.973.6 ± 19.20.857
Ritchie index*14.6 ± 9.5110.36 ± 6.9815.45 ± 9.740.006
Tender entheseal count8.02 ± 2.119.33 ± 3.628.93 ± 4.120.233
BASFI5.58 ± 2.175.11 + 3.095.67 ± 1.940.268
BASDAI**6.39 ± 1.955.35 ± 2.246.60 ± 1.840.021
Dactylitis, n (%)20 (14.70)4 (18.2)16 (14.0)0.742
MetS, n (%)50 (36.76)6 (27.3)44 (38.6)0.347
Bright liver, n (%)51 (38.1)4 (18.2)47 (42.0)0.053
  • * Performed only in subjects with peripheral disease.

  • ** Performed only in subjects with axial disease. SJC: swollen joint count; TJC: tender joint count; PASI: Psoriasis Area and Severity Index; HAQ: Health Assessment Questionnaire; VAS: visual analog scale for pain; BASFI: Bath Ankylosing Spondylitis Functional Index; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; MetS: metabolic syndrome.